TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00972686
Drug: GSK2126458
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2126458 is an experimental treatment for patients with cancer.
Study: NCT01404702
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 4 mg/m2/dose given iv on day 0 of every 28 day cycle
Study: NCT00324363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection twice daily in volumes equal to exenatide
Study: NCT02227888
Drug: N91115
Approvals — FDA: no, EMA: no, PMDA: no
Description: S nitrosoglutathione reductase inhibitor
Study: NCT00215943
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
Study: NCT03332589
Drug: E6201
Normalized name: TRACH STOMA PROTECTOR,CLOTH WHITE BE6201
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6201 formulated in cyclodextrin for IV administration.
Study: NCT03624023
Drug: TWB-103
Approvals — FDA: no, EMA: no, PMDA: no
Description: TWB-103 will be applied to the target ulcer wound once a week by the investigator, starting from Day 1, until wound closure is confirmed or up to 12 weekly applications
Study: NCT01563445
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
Study: NCT04232085
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GVHD prophylaxis
Study: NCT01252199
Drug: cαStx1/cαStx2
Approvals — FDA: no, EMA: no, PMDA: no
Description: cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care
Study: NCT01252199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered over 1 hour + standard of care
Study: NCT01025648
Drug: E004 (epinephrine inhalation aerosol), 125 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E004 (epinephrine inhalation aerosol), 125 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
Study: NCT01025648
Drug: E004 (epinephrine inhalation aerosol), 220 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
Study: NCT03462329
Drug: Antibiotics (preferentially oral doxycycline 100 mg bid)
Normalized name: doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with antibiotics for Lyme disease.
Study: NCT01773798
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
Study: NCT01025648
Drug: epinephrine inhalation aerosol, CFC propelled
Approvals — FDA: no, EMA: no, PMDA: no
Description: epinephrine inhalation aerosol, 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
Study: NCT01025648
Drug: E004 (epinephrine inhalation aerosol), 160 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: E004 (epinephrine inhalation aerosol), 160 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
Study: NCT01512355
Drug: placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline_02mcg/kg/hr
Study: NCT03785756
Drug: Ibuprofen 300 mg Oral Tablet
Normalized name: ibuprofen 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 300 mg tablets at Hours 0 and 12
Study: NCT03785756
Drug: Ibuprofen 200 mg Oral Tablet
Normalized name: IBUPROFEN 200 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 × 200 mg tablets at Hours 0, 8, and 16
Study: NCT03785756
Drug: Placebo of PR tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets up to four times in 24 hours
Study: NCT03785756
Drug: Placebo of IR tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets up to four times in 24 hours
Study: NCT00871494
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.
Study: NCT01539902
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis
Study: NCT02192645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo ointment is composed of flour, buckwheat flour, food colorants and water, resulting in an ointment similar in appearance to the Sanfujiu ointment.
Study: NCT01430416
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00431067
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00475969
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00988429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet given QD
Study: NCT03110640
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients were given cyclophosphamide 500mg/m2/day on day -4.
Study: NCT01074229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injection
Study: NCT01107717
Drug: metformin\pioglitazone\exenatide
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c \< 6.5%
Study: NCT03536520
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT03369119
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01118429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
Study: NCT01448993
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taking 250mg azithromycin 3 times per week in alternate days.
Study: NCT01448993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03498456
Drug: Lansoprazole/Amoxicillin/Clarithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg + Amoxicillin 1000 mg + Clarithromycin 500 mg bid. This therapy will be administered for a total of 7 days, in fasting conditions in the morning and the evening.
Study: NCT00452322
Drug: Testosterone Substitution by Testosterone Undecanoate i.m.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00370747
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00463957
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00399945
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01082354
Drug: recombinant somatropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: as per standard practice
Study: NCT02259959
Drug: Single rising doses of BI 1744 CL, solution for oral inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02259959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01320683
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01320683
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01469429
Drug: chemoprevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive LBR lozenge PO
Study: NCT02099656
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
Study: NCT02099656
Drug: Second Asthma Controller Medication
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
Study: NCT01387464
Drug: ISV-303
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075% bromfenac in DuraSite dosed QD
Study: NCT01387464
Drug: Bromday™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.09% bromfenac dosed QD
Study: NCT03110432
Drug: PCSK9 Inhibitor [EPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug use according to the respective product labelling
Study: NCT03110432
Drug: Standard lipid lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug use according to the respective product labelling
Study: NCT01642030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
Study: NCT04214808
Drug: Avodart Soft Capsule 0.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5mg
Study: NCT00313963
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Placebo (Normal Saline in equivalent amount to magnesium sulfate 100 mg/Kg, Max 2 gram/dose) 8 hourly.
Study: NCT01378533
Drug: epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d\*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d\*8cycles
Study: NCT02444884
Drug: MLN8237
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02188745
Drug: 17B-estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-estrogen
Study: NCT02861716
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.~After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds.
Study: NCT01843920
Drug: standard post-operative topical drops
Normalized name: Sx1 Medicated Post-Operative System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
Study: NCT00244556
Drug: Methotrexate plus ENBREL or ENBREL alone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03770429
Drug: AZD6738
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDS and CMML cells rely specifically on the ATR pathway to fix DNA damage and survive; by inhibiting ATR with AZD6738, MDS or CMML cells appear to selectively accumulate DNA damage and die, but healthy cells appear to be less sensitive to this target
Study: NCT02092909
Drug: IMO-8400
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-8400 at escalating dose levels by subcutaneous injection
Study: NCT00118937
Drug: Placebo.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Placebo (corresponding to 500 mg metformin). Dosage: 1 tablet per day.
Study: NCT00118937
Drug: Placebo.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet Placebo (corresponding to 500 mg metformin). Dosage: 2 tablets two times daily.
Study: NCT02625636
Drug: SAR438544
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT02625636
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Study: NCT04364035
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unit-dose placebo tablet delivered as two 3-mg placebo tablets
Study: NCT03219788
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline will be given
Study: NCT03219788
Drug: Remifentanil 0.1 ug/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.1 ug/kg Remifentanil will be given
Study: NCT03219788
Drug: Remifentanil 0.2 ug/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.2 ug/kg Remifentanil will be given
Study: NCT01782560
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03152409
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.
Study: NCT00635323
Drug: Irinotecan plus capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
Study: NCT01721109
Drug: EVG/COBI/FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150/150/200/300 mg STR administered orally once daily with food
Study: NCT00282386
Drug: MK0966; Rofecoxib / Duration of Treatment: 156 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00282386
Drug: Placebo/ Duration of Treatment: 156 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01009255
Drug: GSK239512
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H3 Antagonist
Study: NCT01009255
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GSK239512
Study: NCT01803945
Drug: AVE8112
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00472368
Drug: LBH589
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04064840
Drug: IVF: Decapeptyl and hCG
Approvals — FDA: no, EMA: no, PMDA: no
Description: When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.
Study: NCT01666210
Drug: Placebo Vehicle Punctum Plug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel punctum plug without dexamethasone
Study: NCT04064840
Drug: FET: Decapeptyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.
Study: NCT04064840
Drug: IVF: hCG and normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.
Study: NCT04064840
Drug: FET: Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the day of FET, normal saline will be injected subcutaneously.
Study: NCT03125161
Drug: HAI
Normalized name: THAIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI
Study: NCT03125161
Drug: chemotherapy ± target therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy ± target therapy
Study: NCT04625985
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to placebo will take a tablet bid (PO) for 14 days in plus standard treatment
Study: NCT02588027
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.
Study: NCT02588027
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacy formulated placebo
Study: NCT02653313
Drug: Parvovirus H-1 (H-1PV)
Normalized name: human parvovirus B19 virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.~The total dose levels are: 1E09, 5E09 and 1E10 pfu.
Study: NCT00571519
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablets matching rivoglitazone tablets administered orally, once daily
Study: NCT00571519
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules for pioglitazone administered orally, once daily
Study: NCT02713776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
Study: NCT01596894
Drug: Azithromycin + Metronidazole
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
Study: NCT01261793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
Study: NCT04031534
Drug: F-Miso PET scan coupled with MRI
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will undergo F-Miso PET and MRI before surgery for their head and neck cancer. Hypoxia detect with imaging will be correlated with hypoxia detected by immunohistochemistry on tumour biopsy
Study: NCT03839485
Drug: Endodontic treatment using Guedes-Pinto Paste
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste is applied
Study: NCT03839485
Drug: Endodontic using Guedes-Pinto Paste without antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental procedure in which the entire pulp chamber is removed from the crown and roots of a tooth and the root filling material Guedes-Pinto paste without antibiotic is applied
Study: NCT05060406
Drug: LY06006
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/1 ml, once every 6 months administered subcutaneously, two injections in total
Study: NCT00363090
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00363090
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04882956
Drug: intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brolucizumab-Dbll intravitreal injection
Study: NCT04882956
Drug: intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aflipercept intravitreal injection
Study: NCT02316821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01298219
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo, 0 mcg administered orally twice daily (BID)
Study: NCT03196180
Drug: Topical Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given intravaginally
Study: NCT03600506
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fifty ml of Placebo (normal saline) will be prepared and given intravenously by a syringe pump over 10 minutes initially and then over 1 hour till the start of wound closure.
Study: NCT00720161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01927484
Drug: 25 mg/week oral methotrexate tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: active oral methotrexate drug
Study: NCT01927484
Drug: 25mg/week oral placebo tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator oral drug
Study: NCT03593187
Drug: Cal-1 (LVsh5/C46) drug product
Normalized name: Cal Gest Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct
Study: NCT01033123
Drug: BSI-201
Normalized name: CENTRAL LINE DRESSING ERASE BSI CHANGE KIT MEDLINE #BSIPICC1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion, 5.6 mg/kg
Study: NCT01358201
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes